ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin Aspart

Also written as “insulin aspart”, “biphasic insulin aspart” and “Faster-acting insulin aspart”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Diabetes, Gestational, led by 9 companies.

Drug pageInsulin Aspart: every studyMany companies study it; this page follows only the 139 they lead. All 207 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 4, 2004139 company-led studies, 1 open or runningNext primary completion: Dec 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only1280 open or runningphase 4since Nov 4, 2004Jul 17, 2003none ahead
Amphastar Pharmaceuticalsits history only20 open or runningphase 3since Sep 12, 2022Sep 12, 2022none ahead
Geropharmits history only20 open or runningphase 3since Sep 3, 2019Sep 3, 2019none ahead
Profil Institut für Stoffwechselforschungits history only20 open or runningphase 1since Aug 8, 2007Aug 8, 2007none ahead
CeQurits history only10 open or runningno phasesince Mar 24, 2015Mar 24, 2015none ahead
Defymedits history only11 open or runningno phasesince Dec 3, 2021Dec 3, 2021Dec 2026NCT05221359
Sunshine Lake Pharmaits history only10 open or runningphase 3since Mar 6, 2023Mar 6, 2023none ahead
The United Laboratories Internationalits history only10 open or runningno phasesince May 6, 2026May 6, 2026none ahead
Tonghua Dongbao Pharmaceutical10 open or runningphase 3since Jun 5, 2015Jun 5, 2015none ahead

Also a collaborator on its studies: Mylan and Sanofi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tonghua Dongbao Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 5, 2015First study: phase 3 study in Diabetes MellitusFirst studyNCT02491528 · 563 enrolled · China

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The one study Tonghua Dongbao Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02491528Diabetes Mellitus · China3CompletedAug 12, 2016563

How it is read

Names in the registry

  • “insulin aspart”, 60 entries
  • “biphasic insulin aspart”, 27 entries
  • “Faster-acting insulin aspart”, 24 entries
  • “biphasic insulin aspart 50”, 13 entries
  • “biphasic insulin aspart 70”, 12 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.